News | Cardiovascular Ultrasound | August 04, 2015

ASE Releases Echo Recommendations for Heart Failure Patients with LVADs

Document examines role of echocardiography across all five phases of patient care

LVADs, heart failure patients, echocardiography, ASE, recommendations, guideline

August 4, 2015 — Over the past several years, advanced heart failure patients who have not responded to medical therapy have been given new hope, and are surviving longer with implanted left ventricular assist devices (LVADs). Although echocardiography is recommended for each phase of care for patients with LVADs, there has been limited published data and no formal guidance for the use of echocardiography in this growing patient population. In an effort to fill this gap, a new document, Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography, will appear in the August 2015 issue of the Journal of the American Society of Echocardiography (JASE).

Usage of this emerging technology has increased exponentially since the U.S. Food and Drug Administration (FDA) approved a newer generation of LVADs in 2008 for patients unable to undergo heart transplantation, with more than 30,000 patients having now received long duration LVADs worldwide. 

The writing group for this guideline was chaired by Raymond F. Stainback, M.D., FASE, medical director of noninvasive cardiac imaging at Texas Heart Institute, in Houston. Stainback noted, “The recent growth of hospital and ambulatory LVAD patients and a lack of consensus on the performance of LVAD echoes has placed a strain on patient care facilities. Our goal with this guideline is to alleviate this situation by providing a convenient reference for the entire mechanical circulatory support team, including practical LVAD echo exam protocols and checklists for timing and performance of echo exams.”

The new guideline document covers the role of echocardiography throughout the five distinct phases of patient care related to LVADs – preoperative patient assessment, perioperative imaging, postoperative surveillance, postoperative problem-focused echocardiography, and recovery protocols. Stainback also commented that “because this is an emerging area, the writing group spent a lot of time and effort to come to consensus, and many of our recommendations are based on expert opinions from high-volume LVAD implant centers. LVAD echo exams can be rather straightforward or uniquely time-consuming and complex, depending upon the situation. However, obtaining the correct information expediently, without disrupting normal echo lab operations, has the potential for improving heart failure care and reducing hospital readmissions.”

In conjunction with the publication of the guideline document, Stainback will conduct a live webinar, including a question and answer section, on Aug. 19, 2015 at 1:00 pm ET.

For more information: www.asecho.org

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Overlay Init